Skip to main content

Table 1 Association between PKM2 expression and clinicopathological features of 173 LUAD patients

From: The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma

Characteristic No. of patients (%) PKM2 expression P-value
Low High
Age (years), median (range) 47 (27–67)    
  ≤ 60 149 (86.1%) 77 (51.7%) 72 (48.3%) 0.080
  > 60 24 (13.9%) 17 (70.8%) 7 (29.2%)
Sex
 Male 124 (71.7%) 67 (54.0%) 57 (46.0%) 0.899
 Female 49 (28.3%) 27 (55.1%) 22 (44.9%)
Smoking history
 Never 118 (68.2%) 64 (54.2%) 54 (45.8%) 0.970
 Current/Former 55 (31.8%) 30 (54.5%) 25 (45.5%)
pT classification
 T1 48 (27.7%) 33 (68.8%) 15 (31.3%) 0.114
 T2 67 (38.7%) 31 (46.3%) 36 (53.7%)
 T3 46 (26.6%) 24 (52.2%) 22 (47.8%)
 T4 12 (6.9%) 6 (50.0%) 6 (50.0%)
pN classification
 N0 100 (57.8%) 62 (62.0%) 38 (38.0%) 0.006
 N1 47 (27.2%) 25 (53.2%) 22 (46.8%)
 N2–3 26 (15.0%) 7 (26.9%) 19 (73.1%)
pM classification
 M0 160 (92.5%) 89 (55.6%) 71 (44.4%) 0.232
 M1 13 (7.5%) 5 (38.5%) 8 (61.5%)
pTNM stage
 I 51 (29.5%) 38 (74.5%) 13 (25.5%) 0.005
 II 66 (38.2%) 33 (50.0%) 33 (50.0%)
 III 43 (24.9%) 18 (41.9%) 25 (58.1%)
 IV 13 (7.5%) 5 (38.5%) 8 (61.5%)
Positive EGFR mutational status 20 (11.6%) 12 (12.8%) 8 (10.1%)  
Positive KRAS mutational status 25 (14.4%) 14 (14.9%) 11 (13.9%)  
Positive ALK translocation status 8 (4.6%) 5 (5.3%) 3 (3.8%)  
  1. PKM2, pyruvate kinase M2; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homologue; ALK, anaplastic lymphoma kinase; LUAD, lung adenocarcinoma